Literature DB >> 29398132

Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development.

Natalia Nowak1, Jan Skupien2, Adam M Smiles3, Masayuki Yamanouchi4, Monika A Niewczas4, Andrzej T Galecki5, Kevin L Duffin6, Matthew D Breyer6, Nick Pullen7, Joseph V Bonventre8, Andrzej S Krolewski9.   

Abstract

To identify determinants of early progressive renal decline in type 2 diabetes a range of markers was studied in 1032 patients enrolled into the 2nd Joslin Kidney Study. eGFR slopes estimated from serial measurements of serum creatinine during 5-12 years of follow-up were used to define early renal decline. At enrollment, all patients had normal eGFR, 58% had normoalbuminuria and 42% had albuminuria. Early renal decline developed in 6% and in 18% patients, respectively. As determinants, we examined baseline values of clinical characteristics, circulating markers: TNFR1, KIM-1, and FGF23, and urinary markers: albumin, KIM-1, NGAL, MCP-1, EGF (all normalized to urinary creatinine) and the ratio of EGF to MCP-1. In univariate analysis, all plasma and urinary markers were significantly associated with risk of early renal decline. When analyzed together, systolic blood pressure, TNFR1, KIM-1, the albumin to creatinine ratio, and the EGF/MCP-1 ratio remained significant with the latter having the strongest effect. Integration of these markers into a multi-marker prognostic test resulted in a significant improvement of discriminatory performance of risk prediction of early renal decline, compared with the albumin to creatinine ratio and systolic blood pressure alone. However, the positive predictive value was only 50% in albuminuric patients. Thus, markers in plasma and urine indicate that the early progressive renal decline in Type 2 diabetes has multiple determinants with strong evidence for involvement of tubular damage. However, new, more informative markers are needed to develop a better prognostic test for such decline that can be used in a clinical setting.
Copyright © 2017 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  diabetes; diabetic nephropathy; microalbuminuria

Mesh:

Substances:

Year:  2018        PMID: 29398132      PMCID: PMC5911430          DOI: 10.1016/j.kint.2017.11.024

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  50 in total

1.  US Renal Data System 2010 Annual Data Report.

Authors:  Allan J Collins; Robert N Foley; Charles Herzog; Blanche Chavers; David Gilbertson; Areef Ishani; Bertram Kasiske; Jiannong Liu; Lih-Wen Mau; Marshall McBean; Anne Murray; Wendy St Peter; Haifeng Guo; Sally Gustafson; Qi Li; Shuling Li; Suying Li; Yi Peng; Yang Qiu; Tricia Roberts; Melissa Skeans; Jon Snyder; Craig Solid; Changchun Wang; Eric Weinhandl; David Zaun; Cheryl Arko; Shu-Cheng Chen; Frederick Dalleska; Frank Daniels; Stephan Dunning; James Ebben; Eric Frazier; Christopher Hanzlik; Roger Johnson; Daniel Sheets; Xinyue Wang; Beth Forrest; Edward Constantini; Susan Everson; Paul Eggers; Lawrence Agodoa
Journal:  Am J Kidney Dis       Date:  2011-01       Impact factor: 8.860

2.  Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes.

Authors:  Monika A Niewczas; Tomohito Gohda; Jan Skupien; Adam M Smiles; William H Walker; Florencia Rosetti; Xavier Cullere; John H Eckfeldt; Alessandro Doria; Tanya N Mayadas; James H Warram; Andrzej S Krolewski
Journal:  J Am Soc Nephrol       Date:  2012-01-19       Impact factor: 10.121

3.  Regression coefficient-based scoring system should be used to assign weights to the risk index.

Authors:  Hemalkumar B Mehta; Vinay Mehta; Cynthia J Girman; Deepak Adhikari; Michael L Johnson
Journal:  J Clin Epidemiol       Date:  2016-05-13       Impact factor: 6.437

4.  CCR2 signaling contributes to ischemia-reperfusion injury in kidney.

Authors:  Kengo Furuichi; Takashi Wada; Yasunori Iwata; Kiyoki Kitagawa; Ken-Ichi Kobayashi; Hiroyuki Hashimoto; Yoshiro Ishiwata; Masahide Asano; Hui Wang; Kouji Matsushima; Motohiro Takeya; William A Kuziel; Naofumi Mukaida; Hitoshi Yokoyama
Journal:  J Am Soc Nephrol       Date:  2003-10       Impact factor: 10.121

5.  Urinary monocyte chemoattractant protein-1 (MCP-1) and connective tissue growth factor (CCN2) as prognostic markers for progression of diabetic nephropathy.

Authors:  Frederick W K Tam; Bruce L Riser; Karim Meeran; JoAnn Rambow; Charles D Pusey; Andrew H Frankel
Journal:  Cytokine       Date:  2009-05-05       Impact factor: 3.861

6.  The ratio of epidermal growth factor to monocyte chemotactic peptide-1 in the urine predicts renal prognosis in IgA nephropathy.

Authors:  D D Torres; M Rossini; C Manno; F Mattace-Raso; C D'Altri; E Ranieri; P Pontrelli; G Grandaliano; L Gesualdo; F P Schena
Journal:  Kidney Int       Date:  2007-10-17       Impact factor: 10.612

7.  Epidermal growth factor and monocyte chemotactic peptide-1 expression in reflux nephropathy.

Authors:  Boris Chertin; Amicur Farkas; Prem Puri
Journal:  Eur Urol       Date:  2003-07       Impact factor: 20.096

8.  NGAL (Lcn2) monomer is associated with tubulointerstitial damage in chronic kidney disease.

Authors:  Thomas L Nickolas; Catherine S Forster; Meghan E Sise; Nicholas Barasch; David Solá-Del Valle; Melanie Viltard; Charles Buchen; Shlomo Kupferman; Maria Luisa Carnevali; Michael Bennett; Silvia Mattei; Achiropita Bovino; Lucia Argentiero; Andrea Magnano; Prasad Devarajan; Kiyoshi Mori; Hediye Erdjument-Bromage; Paul Tempst; Landino Allegri; Jonathan Barasch
Journal:  Kidney Int       Date:  2012-06-13       Impact factor: 10.612

9.  Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria.

Authors:  Andrzej S Krolewski; Monika A Niewczas; Jan Skupien; Tomhito Gohda; Adam Smiles; Jon H Eckfeldt; Alessandro Doria; James H Warram
Journal:  Diabetes Care       Date:  2013-08-12       Impact factor: 19.112

10.  Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study.

Authors:  Monika A Niewczas; Tammy L Sirich; Anna V Mathew; Jan Skupien; Robert P Mohney; James H Warram; Adam Smiles; Xiaoping Huang; Walker Walker; Jaeman Byun; Edward D Karoly; Elizabeth M Kensicki; Gerard T Berry; Joseph V Bonventre; Subramaniam Pennathur; Timothy W Meyer; Andrzej S Krolewski
Journal:  Kidney Int       Date:  2014-01-15       Impact factor: 10.612

View more
  40 in total

1.  Profibrotic Circulating Proteins and Risk of Early Progressive Renal Decline in Patients With Type 2 Diabetes With and Without Albuminuria.

Authors:  Katsuhito Ihara; Jan Skupien; Hiroki Kobayashi; Zaipul I Md Dom; Jonathan M Wilson; Kristina O'Neil; Hannah S Badger; Lenden M Bowsman; Eiichiro Satake; Matthew D Breyer; Kevin L Duffin; Andrzej S Krolewski
Journal:  Diabetes Care       Date:  2020-09-04       Impact factor: 19.112

2.  Increased lipogenesis and impaired β-oxidation predict type 2 diabetic kidney disease progression in American Indians.

Authors:  Farsad Afshinnia; Viji Nair; Jiahe Lin; Thekkelnaycke M Rajendiran; Tanu Soni; Jaeman Byun; Kumar Sharma; Patrice E Fort; Thomas W Gardner; Helen C Looker; Robert G Nelson; Frank C Brosius; Eva L Feldman; George Michailidis; Matthias Kretzler; Subramaniam Pennathur
Journal:  JCI Insight       Date:  2019-11-01

3.  Circulating TNF receptors and risk of renal disease progression, cardiovascular disease events and mortality in patients with diabetes: a systematic review and meta-analysis.

Authors:  Dongsheng Cheng; Yang Fei; Pierre-Jean Saulnier; Niansong Wang
Journal:  Endocrine       Date:  2019-12-07       Impact factor: 3.633

4.  Biomarkers of Chronic Renal Tubulointerstitial Injury.

Authors:  Serena M Bagnasco; Avi Z Rosenberg
Journal:  J Histochem Cytochem       Date:  2019-06-26       Impact factor: 2.479

5.  Initial Validation of a Machine Learning-Derived Prognostic Test (KidneyIntelX) Integrating Biomarkers and Electronic Health Record Data To Predict Longitudinal Kidney Outcomes.

Authors:  Kinsuk Chauhan; Girish N Nadkarni; Fergus Fleming; James McCullough; Cijiang J He; John Quackenbush; Barbara Murphy; Michael J Donovan; Steven G Coca; Joseph V Bonventre
Journal:  Kidney360       Date:  2020-06-30

6.  Sodium Bicarbonate Supplementation and Urinary TGF-β1 in Nonacidotic Diabetic Kidney Disease: A Randomized, Controlled Trial.

Authors:  Kalani L Raphael; Tom Greene; Guo Wei; Tristin Bullshoe; Kunani Tuttle; Alfred K Cheung; Srinivasan Beddhu
Journal:  Clin J Am Soc Nephrol       Date:  2020-01-23       Impact factor: 8.237

Review 7.  Trajectories of kidney function in diabetes: a clinicopathological update.

Authors:  Megumi Oshima; Miho Shimizu; Masayuki Yamanouchi; Tadashi Toyama; Akinori Hara; Kengo Furuichi; Takashi Wada
Journal:  Nat Rev Nephrol       Date:  2021-08-06       Impact factor: 28.314

8.  One-year estimated glomerular filtration rate decline as a risk factor of cardiovascular and renal end-points in high-risk Japanese patients.

Authors:  Shu Meguro; Jun Inaishi; Yasunori Sato; Issei Komuro; Hiroshi Itoh
Journal:  J Diabetes Investig       Date:  2020-12-30       Impact factor: 4.232

9.  Urinary EGF and MCP-1 and risk of CKD after cardiac surgery.

Authors:  Steven Menez; Wenjun Ju; Rajasree Menon; Dennis G Moledina; Heather Thiessen Philbrook; Eric McArthur; Yaqi Jia; Wassim Obeid; Sherry G Mansour; Jay L Koyner; Michael G Shlipak; Steven G Coca; Amit X Garg; Andrew S Bomback; John A Kellum; Matthias Kretzler; Chirag R Parikh
Journal:  JCI Insight       Date:  2021-06-08

10.  Astragaloside IV ameliorates diabetic nephropathy in db/db mice by inhibiting NLRP3 inflammasome‑mediated inflammation.

Authors:  Hui Feng; Xiaoyun Zhu; Yang Tang; Shouqiang Fu; Bingtan Kong; Ximing Liu
Journal:  Int J Mol Med       Date:  2021-07-19       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.